Ceribell, Inc.

EFFECT effective

424B4 priced

Price $17.00 · 10,606,060 shares · Gross proceeds $180,303,020

CERT inactive

EFFECT effective

S-1/A amended

Range $16.00 to $17.00 · 10,606,060 shares

FWP supplemental

Range $16.00 to $17.00

8-A12B effective

S-1/A amended

Range $14.00 to $16.00 · 6,700,000 shares

Ceribell, Inc. is conducting an initial public offering (IPO) to sell 6,700,000 shares of common stock at an expected price range of $14.00 to $16.00 per share. The company aims to list on the Nasdaq Global Market under the symbol 'CBLL.' The offering includes underwriters such as BofA Securities and J.P. Morgan, with a potential 1,005,000 additional shares via an underwriters' option. Ceribell's Ceribell System, a portable EEG platform using AI for seizure detection, targets acute care settings, addressing limitations of traditional EEG systems. The company highlights clinical and economic benefits, including improved patient outcomes and cost savings for hospitals.

S-1/A amended

Ceribell, Inc. is conducting its initial public offering (IPO) to raise capital through the sale of common stock. The company develops the Ceribell System, a portable EEG platform designed to improve seizure detection and management in acute care settings. The S-1/A filing includes updates to the prospectus, reflecting enhanced details on the company's technology, regulatory approvals, and market positioning. The offering is expected to list on the Nasdaq Global Market under the ticker 'CBLL.'

S-1 filed

Ceribell, Inc. is conducting an initial public offering (IPO) to sell shares of its common stock, aiming to list on the Nasdaq Global Market under the symbol 'CBLL.' The company develops the Ceribell System, a portable, AI-powered EEG platform designed for acute care settings to improve seizure detection and management. The filing highlights the system's potential to reduce hospital stays, unnecessary treatments, and healthcare costs. Ceribell emphasizes its status as an emerging growth company and outlines risks related to product dependence, regulatory approvals, and market competition.

DRS/A amended

Ceribell, Inc. is conducting its initial public offering (IPO) by selling common stock, with an expected public offering price range of $ to $ per share. The company aims to list on the Nasdaq Global Market under the symbol 'CBLL'. The Ceribell System, a portable EEG platform using AI for seizure detection, is central to its business. The offering includes underwriters like BofA Securities and J.P. Morgan, with a directed share program for employees. The company emphasizes its focus on improving acute care seizure diagnosis and management.

DRS filed

Ceribell, Inc. is conducting an initial public offering (IPO) of its common stock, with the filing submitted confidentially under Form DRS. The company, a medical technology firm, develops the Ceribell System, a portable EEG platform designed to improve seizure detection and management in acute care settings. The offering price range and exact terms are尚未确定, and the company plans to list on a stock exchange under the ticker 'CBLL'. Ceribell is an emerging growth company and smaller reporting company, which affects its regulatory reporting requirements. The filing notes the omission of recent financial statements, with plans to include them in future amendments.